Further investigations into the efficacy of combining p‐tau measurements with CSF Aβ1‐42 and/or Aβ1‐42/1‐40, and CSF t‐tau have led to CSF p‐tau, particularly p‐tau181, being included in the AT(N) criteria for AD diagnosis and the NIA‐AA research framework for defining AD [9, 20]. Here, MAPT is linked to Alzheimer disease.